Thioridazine, a member of the phenothiazine drug class, is used as a treatment for the symptoms of schizophrenia and other psychotic conditions. However, this drug has reportedly caused many life-threatening issues including cardiac arrythmia. This drug is currently manufactured as a solid state drug and its crystalline structure inhibits its ability to function as expected due to lower aqueous solubility as well as its existence in diferent polymorphic structures. By converting this drug into a liquid form, an ionic liquid (IL) or a double salt ionic liquid (DSIL), new, highly viscous liquid state drugs with new, more desirable properties (e.g., increased aqueous solubility and retained activity) will be obtained.<br/><br/>This presentation focuses on combining various molar ratios of thioridazine, as a cation precursor, with lidocaine cation and docusate anion to create multifunctional DSILs. The two ionic components, lidocaine cation and docusate anion, are added to combat thioridazine’s negative side effect of cardiac arrythmia and to provide the drug with extra delivery options (i.e., transdermal delivery). Three new DSILs were synthesized using the strategies reported in the literature and their aqueous solubility in phosphate buffer saline (pH = 7.4) was investigated.

Solubility of thioridazine double salt ionic liquids in phosphate buffer saline

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.